AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30372482
Drug: SER (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER (50 to 200 mg/d) + GCBT
Trial: 23955660
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (PC) intervention
Trial: 22945620
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) for depression, 16 to 20 sessions
Trial: 16512088
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of red vine leaf extract AS 195 twice daily (360 mg in total) for six weeks
Trial: 12780674
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (blood concentration 5-10 ng/mL) with MMF and low-dose corticosteroid (stopped after 5 months) and induction with daclizumab
Trial: 12780674
Drug: Standard-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose tacrolimus (blood concentration 10-15 ng/mL) with MMF and standard dose corticosteroid
Trial: 10692620
Drug: dextropropoxyphene napsylate
RxNorm normalized name: Dextropropoxyphene napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextropropoxyphene napsylate 100 mg
Trial: 8223138
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dropropizine
Trial: 8223138
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg levodropropizine
Trial: 8223138
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg dropropizine
Trial: 4036849
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 supplementation (15,000 IU weekly)
Trial: 25872943
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) applied to the study group, once a week for the entire period of hospitalization.
Trial: 25872943
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment ('soft touch') applied to the sham group, once a week for the entire period of hospitalization.
Trial: 25872943
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard medical care only, no additional treatment.
Trial: 23531118
Drug: Glipizide 5
RxNorm normalized name: glipizide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide 5 mg once daily (titrated to 10 mg if needed)
Trial: 21377716
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluticasone furoate and oxymetazoline
Trial: 12530483
Drug: Suppressive oral
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive oral acyclovir 400 mg three times daily
Trial: 7705112
Drug: Clarithromycin in
RxNorm normalized name: clarithromycin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin in combination with rifampin (n = 8)
Trial: 7705112
Drug: Clarithromycin in
RxNorm normalized name: clarithromycin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin in combination with other drugs (aminoglycoside, quinolone, clofazimine, isoniazid, ethambutol, pyrazinamide, minocycline)
Trial: 7705112
Drug: Clarithromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (30 mg/kg daily)
Trial: 26049188
Drug: Rhubarb decontaminate
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb decontaminate group (15-20 g aqueous extract by gastric tube, enema, or peros, twice a day)
Trial: 26049188
Drug: Traditional decontaminate
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional decontaminate group (glycerine enema or glycerol enema, twice a day)
Trial: 22679301
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with intramuscular glucocorticoids (GCs)
Trial: 22679301
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with oral GC tapering scheme
Trial: 22679301
Drug: MTX with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX with oral GCs
Trial: 21385466
Drug: Holistic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holistic therapy (HT) consisting of light physical exercise sessions and a mental stress reduction program administered for two weeks.
Trial: 15299181
Drug: RT with
RxNorm normalized name: NuCort with Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT with DDP (100 mg/m2 on d 2, 22, 42)
Trial: 9043505
Drug: Infusion method
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion method
Trial: 25293387
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril at bedtime for 12 weeks
Trial: 25293387
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril in the morning for 12 weeks
Trial: 17875033
Drug: Serotonergic antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic antidepressants (4-month prophylactic therapy)
Trial: 15713522
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin 50 mg/m2 days 1, 8 and vinorelbine 25 mg/m2 days 1, 8, 15, 22 for four cycles)
Trial: 17950982
Drug: Glucose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose administration (25 g)
Trial: 12191837
Drug: Aspartame solution
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame solution (control)
Trial: 25948287
Drug: healthy lifestyle
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: healthy lifestyle psychoeducational program + improved primary care usual treatment (ITAU)
Trial: 21262099
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of mometasone furoate (MF)
Trial: 20144173
Drug: Red clover-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red clover-derived isoflavone medication
Trial: 17710979
Drug: Combined spinal-epidural
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal-epidural analgesia with intrathecal fentanyl 25 mcg
Trial: 17710979
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine 0.25% 10 ml
Trial: 10551072
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture supported by 2 implants with ball attachments
Trial: 10551072
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture supported by 2 implants with an interconnecting bar
Trial: 10551072
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture supported by 4 interconnected implants
Trial: 8903117
Drug: Intrapulmonary insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapulmonary insulin (100 U ml-1 as an aerosol by oral inhalation after a 12-h fasting)
Trial: 6401551
Drug: Slow sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow sodium tablets and Placebo tablets
Trial: 30814418
Drug: Roasted barley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro)
Trial: 30814418
Drug: Roasted barley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro) in male participants
Trial: 27539539
Drug: High-fat, nondairy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat, nondairy meal 4 hours before dosing
Trial: 27539539
Drug: High-fat, nondairy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat, nondairy meal 2 hours before dosing
Trial: 27539539
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal containing dairy 2 hours before dosing
Trial: 21697773
Drug: CNI elimination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CNI elimination (in patients with baseline CrCl > 50 mL/min)
Trial: 21697773
Drug: CNI minimization
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI minimization (in patients with baseline CrCl > 50 mL/min)
Trial: 20166586
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg emtricitabine
Trial: 8378746
Drug: Very long-chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very long-chain n-3 fatty acids (0.65 g day-1)
Trial: 3535007
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg) plus antacid
Trial: 3535007
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg) plus antacid
Trial: 29149437
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose [15 mg/kg (up to 750 mg)], intravenously on study days 0 and 5
Trial: 29149437
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 cc normal saline), intravenously on study days 0 and 5
Trial: 27098300
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait training after AbobotulinumtoxinA injection
Trial: 27098300
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only AbobotulinumtoxinA injection)
Trial: 21172701
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia and sedation (EMLA 5% cream, midazolam/nitrous oxide)
Trial: 17907111
Drug: tesaglitazar 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesaglitazar 0.5 mg
Trial: 17166340
Drug: tesaglitazar 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesaglitazar 1.0 mg
Trial: 17166340
Drug: tesaglitazar 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesaglitazar 2.0 mg
Trial: 17166340
Drug: tesaglitazar 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesaglitazar 3.0 mg
Trial: 12589230
Drug: Glyburide/metformin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/metformin combination therapy
Trial: 10548357
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cimetidine (Tagamet HB)
Trial: 10548357
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Mylanta (initial 17.5-ml dose with additional doses as needed)
Trial: 1918785
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg every 12 hours or 400 mg every 12 hours during acute phase, followed by 750 mg orally every 12 hours during convalescence phase)
Trial: 1918785
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g every 24 hours during acute phase, followed by 1 g intramuscularly every 24 hours during convalescence phase)
Trial: 6821904
Drug: Dopamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine and Dobutamine combination, 7.5 micrograms/kg/min each
Trial: 31473167
Drug: VRC07-523LS (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (1 mg/kg intravenous)
Trial: 31473167
Drug: VRC07-523LS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (5 mg/kg intravenous)
Trial: 31473167
Drug: VRC07-523LS (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (20 mg/kg intravenous)
Trial: 31473167
Drug: VRC07-523LS (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (40 mg/kg intravenous)
Trial: 31473167
Drug: VRC07-523LS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (5 mg/kg subcutaneous)
Trial: 31473167
Drug: VRC07-523LS (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (20 mg/kg intravenous, 3 doses at 12-week intervals)
Trial: 31473167
Drug: VRC07-523LS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC07-523LS (5 mg/kg subcutaneous, 3 doses at 12-week intervals)
Trial: 29693495
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (n=37)
Trial: 29693495
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (n=44)
Trial: 26822749
Drug: Phenytoin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (4 mg/kg or 6 mg/kg per day for 3 months)
Trial: 17573387
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day UDCA
Trial: 17573387
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day UDCA
Trial: 11322266
Drug: Didanosine once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine once daily
Trial: 10723507
Drug: Didanosine once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine once daily in combination with other drugs
Trial: 7646766
Drug: Chymotrypsin-galactose (CG)
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chymotrypsin-galactose (CG) treatment of sperm
Trial: 7646766
Drug: Culture medium
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture medium treatment of sperm
Trial: 25535650
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg once weekly (QW)
Trial: 23981017
Drug: Prednisolone monotherapy
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone monotherapy (N = 32)
Trial: 9426377
Drug: Pyridostigmine (PD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD, 120 mg p.o., 60 min before OGTT)
Trial: 9426377
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose load (OGTT, 100 g p.o. at 0 min) alone
Trial: 8715845
Drug: Oral temperatures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral temperatures
Trial: 2403908
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily before breakfast
Trial: 31116913
Drug: IVUS-guided drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVUS-guided drug-eluting stent (DES) implantation
Trial: 31116913
Drug: Angiography-guided drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiography-guided drug-eluting stent (DES) implantation
Trial: 26523919
Drug: Preladenant 2
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 2 mg twice daily
Trial: 26523919
Drug: Preladenant 5
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 5 mg twice daily
Trial: 26523919
Drug: Preladenant 10
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 10 mg twice daily
Trial: 28490648
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg once daily (active control)
Trial: 25485880
Drug: Acetaminophen, meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, meloxicam and gabapentin (AMG)
Trial: 25485880
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and meloxicam
Trial: 25485880
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and gabapentin
Trial: 25485880
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four analgesic regimens
Trial: 20825879
Drug: Balanced electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced electrolyte solution (BES)
Trial: 17937086
Drug: 50 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/kg of tinzaparin sodium daily (Group A)
Trial: 17937086
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin daily (Group B)
Trial: 14624187
Drug: Paroxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (60 mg/d)
Trial: 8610735
Drug: MRI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI with intravenous gadolinium contrast and manual mixing of the diffused contrast
Trial: 31355323
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg weekly
Trial: 31355323
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg weekly
Trial: 31355323
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg weekly (after relapse on 0.2 g/kg)
Trial: 31355323
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg weekly (after dose reduction from 0.4 g/kg)
Trial: 10623701
Drug: Oral fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenretinide 200 mg/d for 28 days before surgery
Trial: 10623701
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills for 28 days before surgery
Trial: 31690831
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus vinorelbine (lapatinib 1000 mg daily; vinorelbine 20 mg/m2 D1, D8 q3w)
Trial: 31690831
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2 D1, D8 q3w)
Trial: 25088067
Drug: Extrafine BDP/FF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine BDP/FF NEXThaler(®) 100/6 μg bid
Trial: 25088067
Drug: Extrafine BDP/FF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine BDP/FF pMDI 100/6 μg bid
Trial: 25088067
Drug: Non-extrafine BDP
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-extrafine BDP DPI 100 μg bid
Trial: 19115650
Drug: 0.15% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% levobupivacaine (3.3 ml bolus on demand, 5 mg/hour background infusion)
Trial: 19115650
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine (1 ml bolus on demand, 5 mg/hour background infusion)
Trial: 16804151
Drug: Zopiclone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone (7.5 mg each night)
Trial: 10903050
Drug: Cervical epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical epidural morphine
Trial: 16901644
Drug: Bromocriptine (D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (D2 receptor agonist)
Trial: 8375125
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amlodipine once daily
Trial: 3760403
Drug: Potassium metabisulfite
RxNorm normalized name: Potassium Metabisulfite
DrugBank: Potassium metabisulfite (DB15841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium metabisulfite (K2S2O5, 1 mg/ml) skin testing
Trial: 3760403
Drug: Single‐blind oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐blind oral provocative challenge tests with K2S2O5 (1, 5, 10, 25, and 50 mg)
Trial: 24616448
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride 1,500 mg in beverage form
Trial: 23739654
Drug: 2×‐RDA (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×‐RDA (1.6 g kg(‐1) d(‐1))
Trial: 23739654
Drug: 3×‐RDA (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3×‐RDA (2.4 g kg(‐1) d(‐1))
Trial: 23739654
Drug: RDA (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDA (0.8 g kg(‐1) d(‐1))
Trial: 18422711
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish (FV) treatment, 5% sodium fluoride, applied twice per year
Trial: 7867240
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg/day (increased to 100 mg/day based on response)